entertainment -WSS

entertainment

author：hotspot 2025-10-01 14:14:47 - browse：43294

a person wearing blue dress conducts a finger prick test on another person in a home setting — coverage from STAT — Adobe

The last decade has seen billions of dollars flow into digital health companies that promise to improve outcomes for the 38 million Americans living with type 2 diabetes. Their products aren’t cheap, but in the long term, they pitch to health plans and employers that these digital tools will help cut health care costs by preventing serious complications like amputation and kidney failure.

A systematic review by the Peterson Health Technology Institute found, though, that digital tools used to manage diabetes with the help of finger-stick blood glucose readings don’t result in clinically meaningful improvements over standard care. As a result, they don’t reduce health care spending — they drive it up.

“Most of the solutions in this category do not deliver clinical benefits that justify their cost,” Caroline Pearson, executive director of the institute, told STAT. Despite finding that some populations may benefit, the report concludes that current evidence doesn’t support broader adoption for most products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

WSS

In the gardens at Boston Children's Hospital, families find sanctuary

STAT Report: Patient voices and perspectives

30 years of 'Listening to Prozac'

BIO selects John Crowley as new CEO

UHS says company favors patients whose insurance pays more

What don’t we know about an Alzheimer’s drug side effect?

Wikipedia

entertainment

knowledge

In age of alternative facts, a scholarly course on calling out crap

Disappointing trial forces Pfizer to pivot on obesity medicine plans

New air purifier tech could be key to improving indoor air quality

What to do when lifesaving products contribute to climate change

Malaria cases in Florida and Texas: Here’s what you need to know

Organ aging and disease risk measured by new blood test

Walensky prepares to leave CDC — and Congress — behind

What to do when lifesaving products contribute to climate change

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

J&J to emphasize cancer drugs, stop much of its vaccine research

leisure time

Will the market for weight loss drugs really reach $100 billion?

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Why patients can’t get everything they want on drug pricing

Mayo Clinic plans $5B tech

Flagship Pioneering launches a new biotech in two countries

UHS says company favors patients whose insurance pays more

knowledge

hotspot

explore

leisure time